Stratagene Expands Rights to Molecular Diagnostics Intellectual Property Portfolio; Stratagene Acquires Exclusive Licensing Opti
September 08 2006 - 6:30AM
Business Wire
Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and
marketer of specialized life science research and diagnostic
products, today announced that it has obtained an exclusive option
to evaluate and license a family of patents and patent applications
controlled by AROS Applied Biotechnology ("AROS") of Denmark. Under
the terms of the agreement, Stratagene will have the right to
evaluate and exclusively license the rights to certain gene groups
that have been shown to have predictive capabilities for certain
cancers. Financial terms of the agreement were not disclosed. "We
are very excited about this new agreement with AROS, a leader in
gene analysis and PCR-based testing," said Joseph A. Sorge, MD,
President and CEO of Stratagene. "In addition to our ongoing
relationships with Bayer Healthcare, Focus Diagnostics and the
Sidney Kimmel Cancer Center, we regard this new agreement as
another significant milestone for our molecular diagnostics growth
strategy. Our relationship with Bayer Healthcare currently focuses
on customization of our leading-edge Mx3005P instrument systems for
use on Bayer's molecular diagnostics testing platform. Focus
Diagnostics is utilizing our technology, expertise and
manufacturing capabilities to develop selected molecular
diagnostics kits and products based on certain proprietary
FullVelocity technologies. With the addition of AROS, we believe we
have taken another important step in executing the third facet of
our molecular diagnostics strategy, which is focused on developing
Stratagene-branded test kits and products." AROS is headed by
Torben F. Orntoft, a co-founder and CEO of AROS Applied
Biotechnology, Chief Physician in the Department of Clinical
Biochemistry, Aarhus University Hospital and Professor of Molecular
Cancer Diagnostics, University of Aarhus in Denmark. Mr. Orntoft
has authored more than 100 peer-reviewed journal articles and
specializes in translating molecular oncology diagnostics to array
platforms. "Exclusive access to this innovative intellectual
property will enable us to continue to progress with our molecular
diagnostics strategy," continued Dr. Sorge. "By using sets of genes
that have predictive capabilities for bladder cancer, we believe
that we will be able to internally develop diagnostic test kits,
which should enable the detection of cancer at an earlier stage
than is now possible and provide invaluable guidance to doctors as
they make therapeutic decisions to treat cancers. We believe that
this intellectual property, with its important implications for a
variety of cancers, uniquely positions us to bring to market
technology that will serve unmet needs within molecular
diagnostics." About AROS Applied Biotechnology AROS is a contract
research organization and service laboratory offering molecular
testing to industry and universities worldwide. Services include
sample banking, extraction of molecules, Microarray analysis,
PCR-based testing and large clinical studies. For more information,
visit www.arosab.com. About Stratagene Corporation Stratagene is a
developer, marketer and manufacturer of specialized life science
research and diagnostic products. The Company's life science
research unit supports advances in science by inventing,
manufacturing and distributing products that simplify, accelerate
and improve research. These products are used throughout the
academic, industrial and government research sectors in fields
spanning molecular biology, genomics, proteomics, drug discovery
and toxicology. The Company's diagnostic unit develops and
manufactures products for urinalysis, and high quality automated
instrument and reagent systems that use blood samples to test for
more than 1,000 different allergies and autoimmune disorders. In
addition, by combining its expertise in diagnostics and molecular
biology, as well as its experience with FDA regulatory procedures,
the Company is pursuing opportunities to expand its product
portfolio to include molecular diagnostic kits and instrumentation.
More information is available at www.stratagene.com. Safe Harbor
Statement Certain statements in this news release that are not
historical fact constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Stockholders and other readers are cautioned not to place undue
reliance on these forward-looking statements. Stratagene generally
identifies forward-looking statements by using words like
"believe," "intend," "target," "expect," "estimate," "may,"
"should," "plan," "project," "contemplate," "anticipate," "predict"
or similar expressions. You can also identify forward-looking
statements by discussions of strategies, plans or intentions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors, which may cause the actual results
of Stratagene to be materially different from historical results or
from any results expressed or implied by such forward-looking
statements. Among the important factors that could cause actual
results to differ materially from those contained in or implied by
the forward-looking statements are risks associated with the
company's inability to sufficiently anticipate market needs and
develop products and product enhancements that achieve market
acceptance, the company's ability to compete effectively in the
diagnostics and life science research markets, variability of the
company's quarterly revenues and operating results, the failure of
the company to retain key employees, the company's ability to
obtain additional debt or equity financing, the possibility of
declining sales due in part to a reduction in research and
development budgets or government funding, the company's ongoing
ability to protect its own intellectual property rights and to
avoid violating the intellectual property rights of third parties,
extended manufacturing difficulties and currency fluctuations. For
more information about these and other factors that could cause
actual results to differ materially from those contained in or
implied by the forward-looking statements please see Item "1A. Risk
Factors" included in Stratagene's Annual Report on Form 10-K for
the year ended December 31, 2005 and in other reports filed by
Stratagene from time to time with the Securities and Exchange
Commission, including Quarterly Reports on Form 10-Q.
Stratagene (NASDAQ:STGN)
Historical Stock Chart
From May 2024 to Jun 2024
Stratagene (NASDAQ:STGN)
Historical Stock Chart
From Jun 2023 to Jun 2024